Literature DB >> 28766951

Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?

C F Manthey1, L Eckmann2, V Fuhrmann3.   

Abstract

INTRODUCTION: Infections with Clostridium difficile (CDI) represent a major burden for the health care system. Treatment is generally by antibiotic therapy with metronidazole and vancomycin, but efficacy remains suboptimal. Areas covered: This review discusses established and emerging treatment options for CDI, and current therapeutic guidelines, taking into account disease severity and risk of relapse. Expert commentary: New therapeutic approaches, including antibodies and new classes of antibiotics, and new measures for preventing infection with vaccines are under development in phase II/III clinical trials. We performed a systematic literature review using the search terms 'Clostridium difficile' and 'treatment'.

Entities:  

Keywords:  Clostridium difficile; TcdA; TcdB; bezlotoxumab; cadazolid; fecal microbiota transplantation (FMT); fidaxomicin; metronidazole; recurrence; ridinilazole; teicoplanin; tigecycline; vaccine; vancomycin

Mesh：

Substances：

Year:  2017        PMID： 28766951     DOI： 10.1080/17512433.2017.1362978

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN： 1751-2433            Impact factor:   5.045


  4 in total

1.  Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota.

Authors:  Barbara K Lomeli; Hal Galbraith; Jared Schettler; George A Saviolakis; Wael El-Amin; Blaire Osborn; Jacques Ravel; Keith Hazleton; Catherine A Lozupone; Ronald J Evans; Stacie J Bell; Urs A Ochsner; Thale C Jarvis; Shahida Baqar; Nebojsa Janjic
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  Initial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI).

Authors:  Carolin F Manthey; Darja Dranova; Martin Christner; Andreas Drolz; Stefan Kluge; Ansgar W Lohse; Valentin Fuhrmann
Journal:  Crit Care       Date:  2019-12-09       Impact factor: 9.097

3.  Stool cultures at the ICU: get rid of it!

Authors:  Carolin F Manthey; Darja Dranova; Martin Christner; Laura Berneking; Stefan Kluge; Ansgar W Lohse; Valentin Fuhrmann
Journal:  Ann Intensive Care       Date:  2018-01-18       Impact factor: 6.925

4.  Mechanism of Antibacterial Activity of Bacillus amyloliquefaciens C-1 Lipopeptide toward Anaerobic Clostridium difficile.

Authors:  Jia Lv; Rong Da; Yue Cheng; Xiaohong Tuo; Jie Wei; Kaichong Jiang; Adediji Omolade Monisayo; Bei Han
Journal:  Biomed Res Int       Date:  2020-03-03       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.